Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

MN1 is indispensable for MLL-rearranged acute myeloid leukemia.

Sharma A, Jyotsana N, Gabdoulline R, Heckl D, Kuchenbauer F, Slany RK, Ganser A, Heuser M.

Haematologica. 2019 Aug 14. pii: haematol.2018.211201. doi: 10.3324/haematol.2018.211201. [Epub ahead of print]

2.

HoxA9 transforms murine myeloid cells by a feedback loop driving expression of key oncogenes and cell cycle control genes.

Zhong X, Prinz A, Steger J, Garcia-Cuellar MP, Radsak M, Bentaher A, Slany RK.

Blood Adv. 2018 Nov 27;2(22):3137-3148. doi: 10.1182/bloodadvances.2018025866.

3.

The H3K4 methyltransferase Setd1b is essential for hematopoietic stem and progenitor cell homeostasis in mice.

Schmidt K, Zhang Q, Tasdogan A, Petzold A, Dahl A, Arneth BM, Slany R, Fehling HJ, Kranz A, Stewart AF, Anastassiadis K.

Elife. 2018 Jun 19;7. pii: e27157. doi: 10.7554/eLife.27157.

4.

Five percent of healthy newborns have an ETV6-RUNX1 fusion as revealed by DNA-based GIPFEL screening.

Schäfer D, Olsen M, Lähnemann D, Stanulla M, Slany R, Schmiegelow K, Borkhardt A, Fischer U.

Blood. 2018 Feb 15;131(7):821-826. doi: 10.1182/blood-2017-09-808402. Epub 2018 Jan 8. No abstract available.

5.

The interaction of ENL with PAF1 mitigates polycomb silencing and facilitates murine leukemogenesis.

Hetzner K, Garcia-Cuellar MP, Büttner C, Slany RK.

Blood. 2018 Feb 8;131(6):662-673. doi: 10.1182/blood-2017-11-815035. Epub 2017 Dec 7.

PMID:
29217648
6.

AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia.

Zhou F, Liu Y, Rohde C, Pauli C, Gerloff D, Köhn M, Misiak D, Bäumer N, Cui C, Göllner S, Oellerich T, Serve H, Garcia-Cuellar MP, Slany R, Maciejewski JP, Przychodzen B, Seliger B, Klein HU, Bartenhagen C, Berdel WE, Dugas M, Taketo MM, Farouq D, Schwartz S, Regev A, Hébert J, Sauvageau G, Pabst C, Hüttelmaier S, Müller-Tidow C.

Nat Cell Biol. 2017 Jul;19(7):844-855. doi: 10.1038/ncb3563. Epub 2017 Jun 26.

PMID:
28650479
7.

Protein kinase Msk1 physically and functionally interacts with the KMT2A/MLL1 methyltransferase complex and contributes to the regulation of multiple target genes.

Wiersma M, Bussiere M, Halsall JA, Turan N, Slany R, Turner BM, Nightingale KP.

Epigenetics Chromatin. 2016 Nov 11;9:52. eCollection 2016.

8.

Leukemogenic MLL-ENL Fusions Induce Alternative Chromatin States to Drive a Functionally Dichotomous Group of Target Genes.

Garcia-Cuellar MP, Büttner C, Bartenhagen C, Dugas M, Slany RK.

Cell Rep. 2016 Apr 12;15(2):310-22. doi: 10.1016/j.celrep.2016.03.018. Epub 2016 Mar 31.

9.

The molecular mechanics of mixed lineage leukemia.

Slany RK.

Oncogene. 2016 Oct 6;35(40):5215-5223. doi: 10.1038/onc.2016.30. Epub 2016 Feb 29. Review.

PMID:
26923329
10.

The New Semisynthetic Cardenolide Analog 3β-[2-(1-Amantadine)-1-on-ethylamine]-digitoxigenin (AMANTADIG) Efficiently Suppresses Cell Growth in Human Leukemia and Urological Tumor Cell Lines.

Nolte E, Sobel A, Wach S, Hertlein H, Ebert N, Müller-Uri F, Slany R, Taubert H, Wullich B, Kreis W.

Anticancer Res. 2015 Oct;35(10):5271-5.

PMID:
26408686
11.

From initiation to eradication: the lifespan of an MLL-rearranged therapy-related paediatric AML.

Krumbholz M, Bradtke J, Stachel D, Peters O, Hero B, Holter W, Slany R, Metzler M.

Bone Marrow Transplant. 2015 Oct;50(10):1382-4. doi: 10.1038/bmt.2015.155. Epub 2015 Jul 6. No abstract available.

PMID:
26146805
12.

Retrovirus-Mediated Expression of E2A-PBX1 Blocks Lymphoid Fate but Permits Retention of Myeloid Potential in Early Hematopoietic Progenitors.

Woodcroft MW, Nanan K, Thompson P, Tyryshkin K, Smith SP, Slany RK, LeBrun DP.

PLoS One. 2015 Jun 22;10(6):e0130495. doi: 10.1371/journal.pone.0130495. eCollection 2015.

13.

Pbx3 and Meis1 cooperate through multiple mechanisms to support Hox-induced murine leukemia.

Garcia-Cuellar MP, Steger J, Füller E, Hetzner K, Slany RK.

Haematologica. 2015 Jul;100(7):905-13. doi: 10.3324/haematol.2015.124032. Epub 2015 Apr 24.

14.

DOTting the path to doom: how acceleration of histone methylation leads to leukemia.

Bach C, Slany RK.

Cancer Cell. 2014 Dec 8;26(6):781-782. doi: 10.1016/j.ccell.2014.11.004.

15.

Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia.

Kaeda J, Ringel F, Oberender C, Mills K, Quintarelli C, Pane F, Koschmieder S, Slany R, Schwarzer R, Saglio G, Hemmati P, van Lessen A, Amini L, Gresse M, Vagge E, Burmeister T, Serra A, Carson A, Schwarz M, Westermann J, Jundt F, Dörken B, le Coutre P.

Leuk Lymphoma. 2015 Jul;56(7):2105-13. doi: 10.3109/10428194.2014.981175. Epub 2015 Jan 23.

PMID:
25363400
16.

Insulin-like growth factor 1 is a direct HOXA9 target important for hematopoietic transformation.

Steger J, Füller E, Garcia-Cuellar MP, Hetzner K, Slany RK.

Leukemia. 2015 Apr;29(4):901-8. doi: 10.1038/leu.2014.287. Epub 2014 Sep 25.

PMID:
25252870
17.

Genomic inverse PCR for exploration of ligated breakpoints (GIPFEL), a new method to detect translocations in leukemia.

Fueller E, Schaefer D, Fischer U, Krell PF, Stanulla M, Borkhardt A, Slany RK.

PLoS One. 2014 Aug 19;9(8):e104419. doi: 10.1371/journal.pone.0104419. eCollection 2014.

18.

Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia.

Garcia-Cuellar MP, Füller E, Mäthner E, Breitinger C, Hetzner K, Zeitlmann L, Borkhardt A, Slany RK.

Leukemia. 2014 Jul;28(7):1427-35. doi: 10.1038/leu.2014.40. Epub 2014 Jan 21.

PMID:
24445865
19.

MLL-ENL inhibits polycomb repressive complex 1 to achieve efficient transformation of hematopoietic cells.

Maethner E, Garcia-Cuellar MP, Breitinger C, Takacova S, Divoky V, Hess JL, Slany RK.

Cell Rep. 2013 May 30;3(5):1553-66. doi: 10.1016/j.celrep.2013.03.038. Epub 2013 Apr 25.

20.

Multiple interferon regulatory factor and NF-κB sites cooperate in mediating cell-type- and maturation-specific activation of the human CD83 promoter in dendritic cells.

Stein MF, Lang S, Winkler TH, Deinzer A, Erber S, Nettelbeck DM, Naschberger E, Jochmann R, Stürzl M, Slany RK, Werner T, Steinkasserer A, Knippertz I.

Mol Cell Biol. 2013 Apr;33(7):1331-44. doi: 10.1128/MCB.01051-12. Epub 2013 Jan 22.

21.

MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.

Jiang X, Huang H, Li Z, He C, Li Y, Chen P, Gurbuxani S, Arnovitz S, Hong GM, Price C, Ren H, Kunjamma RB, Neilly MB, Salat J, Wunderlich M, Slany RK, Zhang Y, Larson RA, Le Beau MM, Mulloy JC, Rowley JD, Chen J.

Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19397-402. doi: 10.1073/pnas.1217519109. Epub 2012 Nov 6.

22.

Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia.

Jiang X, Huang H, Li Z, Li Y, Wang X, Gurbuxani S, Chen P, He C, You D, Zhang S, Wang J, Arnovitz S, Elkahloun A, Price C, Hong GM, Ren H, Kunjamma RB, Neilly MB, Matthews JM, Xu M, Larson RA, Le Beau MM, Slany RK, Liu PP, Lu J, Zhang J, He C, Chen J.

Cancer Cell. 2012 Oct 16;22(4):524-35. doi: 10.1016/j.ccr.2012.08.028.

23.

The homeodomain region controls the phenotype of HOX-induced murine leukemia.

Breitinger C, Maethner E, Garcia-Cuellar MP, Slany RK.

Blood. 2012 Nov 8;120(19):4018-27. doi: 10.1182/blood-2011-10-384685. Epub 2012 Sep 18.

PMID:
22990017
24.

Distinct regulation of c-myb gene expression by HoxA9, Meis1 and Pbx proteins in normal hematopoietic progenitors and transformed myeloid cells.

Dassé E, Volpe G, Walton DS, Wilson N, Del Pozzo W, O'Neill LP, Slany RK, Frampton J, Dumon S.

Blood Cancer J. 2012 Jun;2(6):e76. doi: 10.1038/bcj.2012.20. Epub 2012 Jun 29.

25.

HOX genes regulate Rac1 activity in hematopoietic cells through control of Vav2 expression.

Breitinger C, Maethner E, Garcia-Cuellar MP, Schambony A, Fischer KD, Schilling K, Slany RK.

Leukemia. 2013 Jan;27(1):236-8. doi: 10.1038/leu.2012.166. Epub 2012 Jun 20. No abstract available.

PMID:
22713647
26.

DNA damage response and inflammatory signaling limit the MLL-ENL-induced leukemogenesis in vivo.

Takacova S, Slany R, Bartkova J, Stranecky V, Dolezel P, Luzna P, Bartek J, Divoky V.

Cancer Cell. 2012 Apr 17;21(4):517-31. doi: 10.1016/j.ccr.2012.01.021.

27.

MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia.

Monroe SC, Jo SY, Sanders DS, Basrur V, Elenitoba-Johnson KS, Slany RK, Hess JL.

Exp Hematol. 2011 Jan;39(1):77-86.e1-5. doi: 10.1016/j.exphem.2010.09.003. Epub 2010 Sep 18.

28.

Expression of cell-cell interacting genes distinguishes HLXB9/TEL from MLL-positive childhood acute myeloid leukemia.

Wildenhain S, Ruckert C, Röttgers S, Harbott J, Ludwig WD, Schuster FR, Beldjord K, Binder V, Slany R, Hauer J, Borkhardt A.

Leukemia. 2010 Sep;24(9):1657-60. doi: 10.1038/leu.2010.146. Epub 2010 Jul 1. No abstract available.

PMID:
20596032
29.

When speed matters: leukemogenic transformation by MLL fusion proteins.

Slany RK.

Cell Cycle. 2010 Jul 1;9(13):2475-6. No abstract available.

PMID:
20543578
30.

ALK fusion genes in children with atypical myeloproliferative leukemia.

Röttgers S, Gombert M, Teigler-Schlegel A, Busch K, Gamerdinger U, Slany R, Harbott J, Borkhardt A.

Leukemia. 2010 Jun;24(6):1197-200. doi: 10.1038/leu.2010.18. Epub 2010 Apr 29. No abstract available.

PMID:
20428197
31.

Leukemogenic transformation by HOXA cluster genes.

Bach C, Buhl S, Mueller D, García-Cuéllar MP, Maethner E, Slany RK.

Blood. 2010 Apr 8;115(14):2910-8. doi: 10.1182/blood-2009-04-216606. Epub 2010 Feb 3.

PMID:
20130239
32.

Misguided transcriptional elongation causes mixed lineage leukemia.

Mueller D, García-Cuéllar MP, Bach C, Buhl S, Maethner E, Slany RK.

PLoS Biol. 2009 Nov;7(11):e1000249. doi: 10.1371/journal.pbio.1000249. Epub 2009 Nov 24.

33.

Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy.

Meyer M, Rübsamen D, Slany R, Illmer T, Stabla K, Roth P, Stiewe T, Eilers M, Neubauer A.

PLoS One. 2009 Nov 5;4(11):e7768. doi: 10.1371/journal.pone.0007768.

34.

Molecular pathology of mixed-lineage leukemia.

Bach C, Slany RK.

Future Oncol. 2009 Oct;5(8):1271-81. doi: 10.2217/fon.09.96. Review.

PMID:
19852741
35.

Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia.

Röhrs S, Dirks WG, Meyer C, Marschalek R, Scherr M, Slany R, Wallace A, Drexler HG, Quentmeier H.

Mol Cancer. 2009 Oct 16;8:86. doi: 10.1186/1476-4598-8-86.

36.

Homing and invasiveness of MLL/ENL leukemic cells is regulated by MEF2C.

Schwieger M, Schüler A, Forster M, Engelmann A, Arnold MA, Delwel R, Valk PJ, Löhler J, Slany RK, Olson EN, Stocking C.

Blood. 2009 Sep 17;114(12):2476-88. doi: 10.1182/blood-2008-05-158196. Epub 2009 Jul 7.

PMID:
19584403
37.

The molecular biology of mixed lineage leukemia.

Slany RK.

Haematologica. 2009 Jul;94(7):984-93. doi: 10.3324/haematol.2008.002436. Epub 2009 Jun 16. Review.

38.

Identification of protein interaction partners by the yeast two-hybrid system.

Garcia-Cuellar MP, Mederer D, Slany RK.

Methods Mol Biol. 2009;538:347-67. doi: 10.1007/978-1-59745-418-6_18.

PMID:
19277583
39.

Alterations of the CxxC domain preclude oncogenic activation of mixed-lineage leukemia 2.

Bach C, Mueller D, Buhl S, Garcia-Cuellar MP, Slany RK.

Oncogene. 2009 Feb 12;28(6):815-23. doi: 10.1038/onc.2008.443. Epub 2008 Dec 8.

PMID:
19060922
40.

A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification.

Mueller D, Bach C, Zeisig D, Garcia-Cuellar MP, Monroe S, Sreekumar A, Zhou R, Nesvizhskii A, Chinnaiyan A, Hess JL, Slany RK.

Blood. 2007 Dec 15;110(13):4445-54. Epub 2007 Sep 12.

41.

Interaction of MLL amino terminal sequences with menin is required for transformation.

Caslini C, Yang Z, El-Osta M, Milne TA, Slany RK, Hess JL.

Cancer Res. 2007 Aug 1;67(15):7275-83.

42.

MLL chimeric protein activation renders cells vulnerable to chromosomal damage: an explanation for the very short latency of infant leukemia.

Eguchi M, Eguchi-Ishimae M, Knight D, Kearney L, Slany R, Greaves M.

Genes Chromosomes Cancer. 2006 Aug;45(8):754-60.

PMID:
16688745
43.

ArgBP2, encoding a negative regulator of ABL, is fused to MLL in a case of infant M5 acute myeloid leukemia involving 4q35 and 11q23.

Pession A, Lo Nigro L, Montemurro L, Serravalle S, Fazzina R, Izzi G, Nucifora G, Slany R, Tonelli R.

Leukemia. 2006 Jul;20(7):1310-3. Epub 2006 Apr 20. No abstract available.

PMID:
16628191
44.

c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells.

Hess JL, Bittner CB, Zeisig DT, Bach C, Fuchs U, Borkhardt A, Frampton J, Slany RK.

Blood. 2006 Jul 1;108(1):297-304. Epub 2006 Feb 28.

45.
46.

Chromatin control of gene expression: mixed-lineage leukemia methyltransferase SETs the stage for transcription.

Slany RK.

Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14481-2. Epub 2005 Oct 3. No abstract available.

47.

When epigenetics kills: MLL fusion proteins in leukemia.

Slany RK.

Hematol Oncol. 2005 Mar;23(1):1-9. Review.

PMID:
16118769
48.

The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin.

Zeisig DT, Bittner CB, Zeisig BB, García-Cuéllar MP, Hess JL, Slany RK.

Oncogene. 2005 Aug 18;24(35):5525-32.

PMID:
15856011
49.

Direct physical and functional interaction of the NuA4 complex components Yaf9p and Swc4p.

Bittner CB, Zeisig DT, Zeisig BB, Slany RK.

Eukaryot Cell. 2004 Aug;3(4):976-83.

50.

Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization.

Zeisig BB, Milne T, García-Cuéllar MP, Schreiner S, Martin ME, Fuchs U, Borkhardt A, Chanda SK, Walker J, Soden R, Hess JL, Slany RK.

Mol Cell Biol. 2004 Jan;24(2):617-28.

Supplemental Content

Support Center